ORBIMED ADVISORS LLC 13D and 13G filings for Ikena Oncology, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-07-30 9:28 pm Purchase | 2025-07-25 | 13D | Ikena Oncology, Inc. IKNA | ORBIMED ADVISORS LLC | 773,754 6.920% | 106,345 (+15.93%) | Filing |
| 2025-06-18 8:23 pm Purchase | 2025-06-14 | 13D | Ikena Oncology, Inc. IKNA | ORBIMED ADVISORS LLC | 667,409 16.710% | 484,984 (+265.85%) | Filing |
| 2023-09-21 4:52 pm Sale | 2023-08-04 | 13D | Ikena Oncology, Inc. IKNA | ORBIMED ADVISORS LLC | 182,426 5.200% | -12,760 (-6.54%) | Filing |
| 2023-09-14 4:21 pm Purchase | 2023-08-04 | 13D | Ikena Oncology, Inc. IKNA | ORBIMED ADVISORS LLC | 195,186 5.500% | 33,779 (+20.93%) | Filing |
| 2021-08-16 4:45 pm Unchanged | 2021-08-12 | 13D | Ikena Oncology, Inc. IKNA | ORBIMED ADVISORS LLC | 161,407 5.400% | 0 (Unchanged) | Filing |
| 2021-04-14 7:31 pm Purchase | 2021-03-30 | 13D | Ikena Oncology, Inc. IKNA | ORBIMED ADVISORS LLC | 161,407 6.560% | 161,407 (New Position) | Filing |